deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02468128

A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management

A Randomized, Double Blind, Placebo-Controlled, Single Dose Study to Assess The Safety and Efficacy of Intramuscular Sebacoyl Dinalbuphine Ester (SDE) for Post-Hemorrhoidectomy Pain Management

Sponsor: Lumosa Therapeutics Co., Ltd.

Conditions Analgesia Disorder Pain
Interventions Placebo Sebacoyl Dinalbuphine Ester
Updated 8 times since 2017 Last updated: Jan 4, 2026 Started: Dec 31, 2012 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Analgesia Disorder and Pain, this trial is completed. The trial is conducted by Lumosa Therapeutics Co., Ltd. and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshotCompleted~Feb 2026 – present · 5 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE2/PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lumosa Therapeutics Co., Ltd.
Data source: Lumosa Therapeutics Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations